307 related articles for article (PubMed ID: 31114700)
1. Eligibility of patients with type 2 diabetes for sodium-glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study.
Pintat S; Fenici P; Hammar N; Ji L; Khunti K; Medina J; Tang F; Wittbrodt E; Surmont F
BMJ Open Diabetes Res Care; 2019; 7(1):e000627. PubMed ID: 31114700
[TBL] [Abstract][Full Text] [Related]
2. Eligibility varies among the 4 sodium-glucose cotransporter-2 inhibitor cardiovascular outcomes trials: implications for the general type 2 diabetes US population.
Wittbrodt ET; Eudicone JM; Bell KF; Enhoffer DM; Latham K; Green JB
Am J Manag Care; 2018 Apr; 24(8 Suppl):S138-S145. PubMed ID: 29693360
[TBL] [Abstract][Full Text] [Related]
3. Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice.
Nicolucci A; Candido R; Cucinotta D; Graziano G; Rocca A; Rossi MC; Tuccinardi F; Manicardi V
Adv Ther; 2019 Oct; 36(10):2895-2909. PubMed ID: 31410779
[TBL] [Abstract][Full Text] [Related]
4. Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis.
Castellana M; Procino F; Sardone R; Trimboli P; Giannelli G
Cardiovasc Diabetol; 2020 Jun; 19(1):87. PubMed ID: 32534590
[TBL] [Abstract][Full Text] [Related]
5. Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?
Shao SC; Lin YH; Chang KC; Chan YY; Hung MJ; Kao Yang YH; Lai EC
BMJ Open Diabetes Res Care; 2019 Dec; 7(1):. PubMed ID: 32043472
[TBL] [Abstract][Full Text] [Related]
6. How representative of a general type 2 diabetes population are patients included in cardiovascular outcome trials with SGLT2 inhibitors? A large European observational study.
Birkeland KI; Bodegard J; Norhammar A; Kuiper JG; Georgiado E; Beekman-Hendriks WL; Thuresson M; Pignot M; Herings RMC; Kooy A
Diabetes Obes Metab; 2019 Apr; 21(4):968-974. PubMed ID: 30537226
[TBL] [Abstract][Full Text] [Related]
7. Class effects of SGLT2 inhibitors on cardiorenal outcomes.
Kluger AY; Tecson KM; Lee AY; Lerma EV; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
Cardiovasc Diabetol; 2019 Aug; 18(1):99. PubMed ID: 31382965
[TBL] [Abstract][Full Text] [Related]
8. How Many Patients with Type 2 Diabetes Meet the Inclusion Criteria of the Cardiovascular Outcome Trials with SGLT2 Inhibitors? Estimations from a Population Database in a Mediterranean Area.
Canivell S; Mata-Cases M; Vlacho B; Gratacòs M; Real J; Mauricio D; Franch-Nadal J
J Diabetes Res; 2019; 2019():2018374. PubMed ID: 31815146
[TBL] [Abstract][Full Text] [Related]
9. Cardiorenal Outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME Trials: A Systematic Review.
Kluger AY; Tecson KM; Barbin CM; Lee AY; Lerma EV; Rosol ZP; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
Rev Cardiovasc Med; 2018 Jun; 19(2):41-49. PubMed ID: 31032602
[TBL] [Abstract][Full Text] [Related]
10. Eligibility of patients with type 2 diabetes for sodium-glucose co-transporter-2 inhibitor cardiovascular outcomes trials: An assessment using the Diabetes Collaborative Registry.
Wittbrodt E; Chamberlain D; Arnold SV; Tang F; Kosiborod M
Diabetes Obes Metab; 2019 Aug; 21(8):1985-1989. PubMed ID: 30968543
[TBL] [Abstract][Full Text] [Related]
11. External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular disease.
Smidt LCA; Visseren FLJ; de Ranitz-Greven WL; Nathoe HM; Kappelle LJ; de Borst GJ; de Valk HW; Westerink J;
Cardiovasc Diabetol; 2021 Sep; 20(1):181. PubMed ID: 34496847
[TBL] [Abstract][Full Text] [Related]
12. Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
Handelsman Y
Adv Ther; 2019 Oct; 36(10):2567-2586. PubMed ID: 31444707
[TBL] [Abstract][Full Text] [Related]
13. Sodium-glucose co-transporter-2 inhibitor cardiovascular outcome trials and generalizability to English primary care.
Hinton W; Feher M; Munro N; Joy M; de Lusignan S
Diabet Med; 2020 Sep; 37(9):1499-1508. PubMed ID: 32128875
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
Scheen AJ
Circ Res; 2018 May; 122(10):1439-1459. PubMed ID: 29748368
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease.
Reifsnider OS; Kansal AR; Gandhi PK; Cragin L; Brand SB; Pfarr E; Fahrbach K; Ustyugova A
BMJ Open Diabetes Res Care; 2021 May; 9(1):. PubMed ID: 33941549
[TBL] [Abstract][Full Text] [Related]
16. [Cardiovascular and renal protection with SGLT2 inhibitors: from EMPA-REG OUTCOME to VERTIS CV].
Scheen AJ
Rev Med Suisse; 2020 Aug; 16(703):1483-1488. PubMed ID: 32852168
[TBL] [Abstract][Full Text] [Related]
17. The kidney and cardiovascular outcome trials.
Bloomgarden Z
J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
[TBL] [Abstract][Full Text] [Related]
18. [Outcome studies on SGLT-2 inhibitors].
Seufert J; Laubner K
Internist (Berl); 2019 Sep; 60(9):903-911. PubMed ID: 31375850
[TBL] [Abstract][Full Text] [Related]
19. Estimating the number of preventable cardiovascular disease events in the United States using the EMPA-REG OUTCOME trial results and National Health and Nutrition Examination Survey.
Wong ND; Fan W; Pak J
Diab Vasc Dis Res; 2020; 17(4):1479164120945674. PubMed ID: 32722930
[TBL] [Abstract][Full Text] [Related]
20. Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials.
Kamstra R; Durkin M; Cai J; Bookhart B; Lafeuille MH; Pilon D; Tiggelaar S; Manceur AM; Lefebvre P
J Med Econ; 2019 Mar; 22(3):280-287. PubMed ID: 30575426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
